Aromatase inhibitor (Anastrozole) improves near adult height (AH) in growth hormone treated adolescents with Prader-Willi syndrome
Journal of Endocrinological Investigation · 03.11.2026
DOI: 10.1007/s40618-026-03046-4 ↗Kurz gefasst
Fachartikel in der Zeitschrift Journal of Endocrinological Investigation, online erschienen am 03.11.2026. Verfasst von Moris A Angulo und 1 weiteren Autor:innen. Beteiligte Einrichtung: Department of Pediatrics, Good Samaritan University Hospital, West Islip, New York, USA. Die Arbeit nennt 40 Literaturangaben. Gefördert von: Eunice Kennedy Shriver National Institute of Child Health and Human Development.
Abstract (Originalsprache)
Purpose
Prader-Willi syndrome (PWS) is a complex multisystemic genetic condition characterized by obesity, short stature and growth with other hormone deficiencies. Aromatase inhibitors (AI) delay estrogen-driven epiphyseal fusion and may enhance near adult height (AH). We investigated whether Anastrozole, a potent aromatase inhibitor, could impact AH in adolescent boys with PWS treated with growth hormone (GH).
Methods
We undertook a retrospective designed study of two groups of boys diagnosed with PWS at a young age and treated with GH. Eighteen boys treated with GH alone (GHA) were compared to 19 boys treated with GH and AI added between 10 and 13 years of age. Height, weight and bone age were tracked. We analyzed AH achieved in those treated with GH alone (GHA) vs. GH plus AI (GHAI). ANOVA was used for data analysis.
Results
More advanced bone age and a higher body mass index were found in both subject groups and a slowdown of skeletal maturation in the treated GHAI group. Mean age after reaching AH for the GHA group was 14.2 years and 17.2 years for the GHAI group. The mean AH standard deviation score (AH-SDS) before and after treatment in the GHA group was -1.8 ± 1.5 /0.11 ± 1.0 and -0.85 ± 0.7/0.81 ± 0.9 for GHAI, both significant ( p < 0.0001), and difference between AH-SDS was also significantly greater in the GHAI group [1.01 ± 0.33 ( p = 0.004)].
Conclusion
Increased adiposity and premature adrenarche may accelerate growth velocity in PWS children and decreased AH. Anastrozole was effective in slowing bone maturation and improving AH in GH treated adolescents without significant side effects.
Schlagwörter
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Department of Pediatrics, Good Samaritan University Hospital, West Islip, New York, USA.
- Departments of Psychiatry & Behavioral Sciences and Pediatrics, Kansas University Medical Center, Kansas City, KS, USA. mbutler4@kumc.edu.
Förderung
- Eunice Kennedy Shriver National Institute of Child Health and Human Development
Zitieren
APA
Angulo, M. A., & Butler, M. G. (2026). Aromatase inhibitor (Anastrozole) improves near adult height (AH) in growth hormone treated adolescents with Prader-Willi syndrome. Journal of Endocrinological Investigation. https://doi.org/10.1007/s40618-026-03046-4
Vancouver
Angulo MA, Butler MG. Aromatase inhibitor (Anastrozole) improves near adult height (AH) in growth hormone treated adolescents with Prader-Willi syndrome. Journal of Endocrinological Investigation. 2026. doi:10.1007/s40618-026-03046-4
BibTeX
@article{Angulo2026,
author = {Angulo, Moris A and Butler, Merlin G},
title = {Aromatase inhibitor (Anastrozole) improves near adult height (AH) in growth hormone treated adolescents with Prader-Willi syndrome},
journal = {Journal of Endocrinological Investigation},
year = {2026},
doi = {10.1007/s40618-026-03046-4}
}
EUVIMED